HMC introduces innovative therapies for depression in Mesaieed General Hospital

QATAR—Hamad Medical Corporation (HMC) has released two innovative therapy solutions for individuals suffering from treatment-resistant depression: esketamine and Transcranial Magnetic Stimulation (TMS).

These novel therapies are now offered at Mesaieed General Hospital’s Mental Health Service, representing a significant advancement in mental health care in Qatar.

According to Dr. Ovais Wadoo, senior consultant and clinical head for Neuromodulation Services at HMC, esketamine is a promising new treatment option for people who have not reacted well to standard antidepressants.

When administered as a nasal spray, esketamine has demonstrated significant potential in alleviating the limitations of conventional treatments in patients.

When other types of treatment have failed, it provides patients with a new chance at recovery.

The US Food and Drug Administration (FDA) has approved ketamine, ensuring its safety and efficacy.

The treatment is administered under strict medical supervision in a clinical environment, ensuring patients receive the care and monitoring necessary for optimal outcomes.

 Dr. Wadoo highlighted that this therapy is particularly beneficial for patients who have not experienced improvements with other antidepressants, offering them a new path toward better mental health.

In addition to esketamine, HMC will soon roll out Transcranial Magnetic Stimulation (TMS), a non-invasive therapy that uses magnetic pulses to stimulate targeted areas of the brain linked to mood regulation.

This advanced technique offers an alternative for patients who either cannot tolerate the side effects of traditional medications or have not seen the desired results from them.

TMS provides a new approach to treating depression without the drawbacks of medication, offering hope to those in need of an alternative treatment option.

Both esketamine and TMS have gained recognition from global mental health experts for their effectiveness in alleviating symptoms of depression.

Esketamine is known for its ability to deliver rapid relief, often providing improvements in mood and well-being for patients who have not responded to other forms of treatment.

Similarly, TMS has demonstrated long-lasting benefits, enhancing not only mood but also overall functionality, allowing patients to regain control of their lives.

The introduction of these treatments at HMC aligns with Qatar’s National Vision 2030, which emphasizes the importance of mental health as a key element of overall well-being.

It also supports the goals outlined in the upcoming National Health Strategy 2024-2030, which prioritizes expanding access to innovative mental health care services.

By offering these advanced therapies, HMC is contributing to the development of a healthier society, ensuring that individuals with mental health challenges receive the highest quality care available.

Sign up to receive our email newsletters with the latest news updates and  insights from Africa and the World HERE